Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2015.06.046 | DOI Listing |
Publication Analysis
Top Keywords
inflammatory bowel
8
bowel disease
8
biarylsulfonamide ccr9
4
ccr9 inhibitors
4
inhibitors inflammatory
4
disease inflammatory
4
disease including
4
including crohn's
4
crohn's disease
4
disease ulcerative
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!